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Michael Neuberger’s untimely death on 
October 26 last year was a shock for his friends 
and the scientific community. The many 
obituaries written about him by friends and 
colleagues testify to his unique, overarching 
stature as a scientist, colleague, and human 
companion. I am writing this retrospective 
mourning a personal friend and irreplaceable 
loss. 
Michael’s father, Albert Neuberger, came from 
a Jewish family in southern Germany, where he 
got his education as a biochemist but lost his 
position shortly after Hitler came to power, and 
emigrated to the United Kingdom, which 
became his home country. He pursued a highly 
successful academic career in Cambridge and 
London, and became one of the leading 
biochemists in the country and an elected 
Fellow of the Royal Society. He and his wife 
Lilian née Dreyfus had four sons, who all 
pursued distinguished careers in higher 
education. Michael, the youngest, studied 
Natural Sciences at Cambridge and then did his 
PhD work in Brian Hartley’s laboratory at 
Imperial College in London, on gene 
duplication in bacteria. On the basis of this 
work, he was elected to a Research Fellowship 
at Trinity College, Cambridge, and it was there 
that Michael sought advice from Sidney 
Brenner at the Medical Research Council 
laboratory of Molecular Biology (LMB) about 
how to pursue his interest in the emerging area 
of molecular immunology. Sidney referred him 
to César Milstein (whose mentor at the LMB 
had been Fred Sanger, a former PhD student of 
Albert Neuberger), who had developed, with 
Georges Köhler, the hybridoma technique for 
the production of monoclonal antibodies, a 
Nobel-winning achievement. To my personal 
good luck, César advised Michael to first do a 
postdoc in my laboratory in Cologne, Germany, 
to learn some immunology.  
Thus, one day in 1979, Michael appeared in my 
office at the Genetics Institute to explore the 
situation. We had just learned, with César’s 
help, to produce monoclonal antibodies, and 
had begun to use the hybridoma technique for 
various purposes, among them the dissection of 
the antibody response itself. After having spent 
a day of discussions in the laboratory, Michael 
decided to join ongoing efforts to isolate 
somatic cell variants by fluorescence-activated 
cell sorting (FACS), with the help of 
monoclonal antibodies recognizing different 
epitopes on a given target cell-surface molecule. 
His molecule of choice was surface Ig on 
hybridoma cells, where he planned to isolate 
variants that had selectively lost a variable 
region determinant (as recognized by an “anti-
idiotypic” monoclonal antibody), and thus to 
study somatic antibody diversification, the 
subject that would occupy him until the end of 
his life.  
It was clear from the first minute that Michael 
was an exceptional, almost frighteningly clever 
young scientist. Bare of any real knowledge of 
immunology, he produced an EMBO long-term 
fellowship application in a single morning in 
the institute’s library, to be sent off—essentially 
unmodified—in the afternoon of the same day, 
and granted shortly thereafter. The eighteen 
months he spent with us were most enjoyable, 
entertaining, and productive, although the 
hybridoma cells turned out to be unsuitable for 
the study of antibody somatic hypermutation 
(SHM). Thus, when Michael returned to the 
LMB in Cambridge, he had familiarized himself 
with immunology and published two interesting 
papers on families of monoclonal antibodies 
sharing identical V regions although differing in 
antibody class, but SHM remained to be 
resolved. The future looked bright, however, 
with him and César Milstein working at the 
LMB side-by-side.  
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Using the antibody system to study the control 
of gene expression at a molecular level, 
Michael discovered and characterized enhancer 
elements in the Ig gene loci and developed, 
together with his office neighbor Greg Winter 
and others, the first tools for the expression and 
engineering of recombinant and humanized 
antibodies. He thus became one of the founders 
of this vast field of present-day “translational” 
research. However, his main interest remained 
the control of the antibody response. Although 
he contributed in highly original and major 
ways to such issues as the mechanisms of B-
cell activation by antigen and of immunological 
tolerance, his real passion continued to be the 
problem of the somatic diversification of 
antibody specificity. And it is here that his 
scientific genius struck most dramatically.  
Following the generation of the primary 
antibody repertoire by Ig gene rearrangements, 
antibodies are further diversified by SHM and 
class-switch recombination (CSR), a process by 
which antibodies acquire distinct effector 
functions. A third diversification mechanism 
was discovered during those years, namely the 
modification of expressed variable region genes 
in chickens, through gene conversion mediated 
by upstream pseudogenes. Work on these issues 
was carried out in many laboratories around the 
world, including the compilation of large sets of 
DNA sequences, from which salient features of 
the SHM process became apparent. Michael 
and the LMB group were involved at all levels 
and repeatedly came up with conceptually new 
insights. Thus, during a time in which analyses 
of the role of error-prone DNA polymerases in 
SHM were in the center of interest, along the 
lines of the 1966 Brenner-Milstein model of 
SHM, Neuberger and colleagues interpreted 
differences in the targeting of C:G versus A:T 
base pairs in certain cell lines and upon ablation 
of a mismatch repair-sensing enzyme as a 
reflection of two distinct stages of SHM, with 
the targeting of C:G pairs (and C:G-based 
mutational hot spots) at its initiation. Further, 
working on Ig gene conversion, they produced 
genetic evidence that the gene conversion 
process could be converted into SHM by 
ablation of components of the homologous 
recombination machinery. And finally, they 
came up with the notion that SHM and CSR, 
although seemingly distinct processes, may be 
mechanistically related.  
Thus, when in a landmark discovery Activation 
Induced Cytidine Deaminase (AID) was 
identified by Tasuku Honjo’s group in 1999 and 
subsequently shown to control both SHM and 
CSR in mice and humans (and later, also gene 
conversion in chickens), Michael’s mind was 
set to interpret AID function not in the context 
of its homology to APOBEC1, an RNA-editing 
enzyme, but in the frame of the idea of an initial 
targeting of C:G base pairs in DNA. To quote 
him (1), “It was an interleaving of the discovery 
of AID with previous information about 
antibody mutation spectra that led [me] to the 
formulation of the DNA deamination model of 
antibody diversification” (1). In the by now 
famous paper describing the new model (2), 
Neuberger and colleagues presented evidence in 
bacteria that AID could indeed function as a 
DNA mutator through C→U conversion. In a 
flurry of subsequent papers from Neuberger and 
colleagues and several other groups, the DNA 
deamination model received further support 
from biochemical and genetic experiments, 
including analyses in chicken, mouse, and 
human B cells, and is now widely accepted in 
the community.  
For Michael, these times of scientific synthesis, 
with a unifying mechanism of 
postrearrangement antibody diversification 
emerging, must have been deeply satisfying. In 
the spring of 2002, he contacted me at the 
Center for Blood Research at Harvard Medical 
School and, in an unusual initiative, offered to 
give a seminar. This memorable event took 
place on July 30 at 9:30 AM in our packed 
small lecture hall, a few weeks after his paper 
on the deamination model (2) had appeared. 
Since then, it has become apparent that DNA 
deamination by APOBEC family members 
plays a critical role beyond the immune system, 
in processes such as intracellular defense 
against viruses and acquisition of mutations in 
cancerogenesis. Michael contributed 
substantially to this new field of research. In a 
paper typical for him in its elegance, published 
a few months before his death, he and his 
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colleagues showed that in a yeast model system 
APOBEC proteins can generate large stretches 
of clustered mutations similar to the “kataegis” 
seen in many cancers (3).  
Michael stayed at the LMB, where he became 
head of the Protein and Nucleic Acid Division 
and deputy director. He always worked with 
only a small group of people. He received many 
awards and honors, prominently among them 
his election to the Royal Society at young age, 
and in 2013, the National Academy of Sciences 
of the USA as a Foreign Associate. He was a 
brilliant scientist of the highest caliber and an 
inspiring, caring academic teacher, colleague, 
and friend, with a genuine interest in other 
people’s work and lives, always being 
encouraging, full of energy, and ready to help. 
Deeply attached to his family and homes in 
Cambridge and East Anglia, he loved to travel 
because of his insatiable curiosity about the 
world. He spoke affectionately and with great 
respect about collaborators and colleagues, 
notably also the young group leaders he 
mentored at the LMB, and he has left his mark 
on generations of young scientists. Meeting him 
was like continuing an uninterrupted dialogue, 
about science, books, history, and whatever else 
was on one’s mind. I still cannot believe that 
this dialogue has now ended.  
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Fig.1: Michael Neuberger at the Genetics Institute in 
Cologne, 1981 (A), and together with the author at a 
FEBS course on immunology in Croatia in 2007 (B). 
Michael had been teaching and inspiring young scientists 
at this biannual summer school for decades. 
 
